Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

BioNexus Gene Lab Corp Common stock

Basic Materials US BGLC

2.24USD
-0.18(7.44%)

Last update at 2026-06-23T18:07:00Z

Day Range

2.232.47
LowHigh

52 Week Range

1.9215.60
LowHigh

Fundamentals

  • Previous Close 2.42
  • Market Cap5.51M
  • Volume27041
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.98709M
  • Revenue TTM7.42M
  • Revenue Per Share TTM4.00
  • Gross Profit TTM 1.09M
  • Diluted EPS TTM-1.61

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -2.98461M -1.59485M -2.60752M -0.30366M 1.04M
Minority interest - - - - -
Net income -2.98461M -1.59834M -2.62904M -0.35597M 0.75M
Selling general administrative 2.33M 1.97M 2.44M 1.73M 1.20M
Selling and marketing expenses 1.74M 2.03M 0.60M - -
Gross profit 1.09M 1.29M 1.33M 1.26M 2.19M
Reconciled depreciation 0.17M 0.15M 0.10M 0.11M 0.11M
Ebit -2.96507M -1.57370M -2.59359M -0.29118M 1.06M
Ebitda -2.79676M -1.42056M -2.48516M -0.18576M 1.16M
Depreciation and amortization 0.17M 0.15M 0.11M 0.11M 0.11M
Non operating income net other - - - - -0.23395M
Operating income -3.15845M -1.57370M -2.59359M -0.29118M 1.06M
Other operating expenses 10.58M 11.08M 12.36M 11.22M 12.31M
Interest expense 0.02M 0.02M 0.01M 0.01M 0.01M
Tax provision 0.00000M 0.00349M 0.11M 0.05M 0.29M
Interest income 0.08M 0.15M 0.07M - -
Net interest income 0.06M 0.13M -0.01451M -0.01248M -0.01297M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.00349M 0.02M 0.05M 0.29M
Total revenue 7.42M 9.51M 9.77M 10.93M 13.36M
Total operating expenses 4.24M 2.86M 3.92M 1.55M 1.14M
Cost of revenue 6.34M 8.22M 8.44M 9.67M 11.17M
Total other income expense net 0.17M -0.02115M -0.01393M -0.01248M -0.01297M
Discontinued operations - - - - -
Net income from continuing ops -2.98461M -1.59834M -3.09343M -0.35597M 0.80M
Net income applicable to common shares - - - - 0.75M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 9.25M 10.43M 11.40M 8.74M 9.57M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 1.74M 0.08M 0.12M 1.54M 0.07M
Total liab 0.64M 2.11M 1.74M 2.08M 2.39M
Total stockholder equity 8.61M 8.32M 9.66M 6.67M 7.18M
Deferred long term liab - - - - -
Other current liab 0.45M 0.30M 0.19M 0.10M 0.17M
Common stock 20.17M 17.33M 17.19M 10.93M 10.78M
Capital stock 20.17M 17.33M 17.19M 10.93M 10.78M
Retained earnings -6.42723M -3.44262M -1.84428M 1.16M 1.51M
Other liab - - - - 0.03M
Good will - - - - -
Other assets - - - - -
Cash 2.38M 4.38M 5.93M 2.12M 2.12M
Cash and equivalents - - - - -
Total current liabilities 0.52M 1.95M 1.63M 2.00M 2.33M
Current deferred revenue 0.00839M 0.10M - 0.02M 0.11M
Net debt -2.20732M -4.16687M -5.79594M -2.06209M -2.04697M
Short term debt 0.06M 0.05M 0.03M 0.02M 0.04M
Short long term debt - - - - -
Short long term debt total 0.18M 0.21M 0.13M 0.06M 0.08M
Other stockholder equity -5.01189M -5.01189M -6.85617M -5.01189M -5.01189M
Property plant equipment - - - - 1.63M
Total current assets 5.45M 7.43M 8.05M 6.02M 7.15M
Long term investments 2.03M 1.27M 1.70M 1.15M 0.75M
Net tangible assets - - - - 7.18M
Short term investments - 2.79M 3.31M - -
Net receivables 0.65M 1.58M 0.98M 2.93M 3.44M
Long term debt - - - - -
Inventory 0.68M 1.39M 1.14M 0.98M 1.52M
Accounts payable 0.00233M 1.50M 1.40M 1.86M 2.01M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.12075M -0.55500M -0.67729M -0.40906M -0.10026M
Additional paid in capital - - - - -
Common stock total equity - - - - 10.78M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - 1.51M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - 0.79M
Deferred long term asset charges - - - - -
Non current assets total 3.80M 3.00M 3.35M 2.72M 2.42M
Capital lease obligations 0.18M 0.21M 0.13M 0.06M 0.08M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.96M 0.42M -0.41873M -0.45050M -0.50945M
Change to liabilities - - - - -1.18053M
Total cashflows from investing activities 0.94M 0.42M -1.85561M - -0.49057M
Net borrowings - - 0.00000M - -0.00192M
Total cash from financing activities 0.30M 0.14M 6.27M 0.12M -0.02822M
Change to operating activities - - - - -0.05747M
Net income -2.98461M -1.59834M -2.62904M -0.35597M 0.75M
Change in cash -0.40058M -1.63074M 3.81M -0.00505M -0.66377M
Begin period cash flow 2.89M 4.52M 2.12M 2.12M 2.79M
End period cash flow 2.49M 2.89M 5.93M 2.12M 2.12M
Total cash from operating activities -1.83838M -2.23426M -1.76080M 0.54M 0.00916M
Issuance of capital stock 0.27M 0.00000M 5.75M 0.15M -
Depreciation 0.11M 0.15M 0.11M 0.11M 0.11M
Other cashflows from investing activities -0.04075M 0.15M -1.41163M - 0.02M
Dividends paid 0.02M 0.07M 0.12M -0.00000M -0.02204M
Change to inventory 0.71M -0.25085M -0.16039M 0.54M -0.34575M
Change to account receivables 0.78M 0.15M 0.61M 0.54M 0.58M
Sale purchase of stock - - - - -
Other cashflows from financing activities 0.03M 0.14M 0.52M 0.00000M 0.02M
Change to netincome - - - - 0.00381M
Capital expenditures 0.04M 0.23M 0.15M 0.05M 0.00316M
Change receivables - - - - 0.58M
Cash flows other operating - - - - 0.07M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -0.50963M
Change in working capital -0.62243M 0.12M 0.12M 0.83M -0.86225M
Stock based compensation 0.79M 0.14M 0.51M - -
Other non cash items 0.86M -0.90446M 0.64M -0.03881M 0.01M
Free cash flow -1.87535M -2.46125M -1.91020M 0.49M 0.00600M

Peer Comparison

Sector: Basic Materials Industry: Specialty Chemicals

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BGLC
BioNexus Gene Lab Corp Common stock		 -0.18 7.44% 2.24 - - 0.74 0.64 0.22 629.53
LIN
Linde plc Ordinary Shares		 -4.45 0.86% 512.26 33.77 28.90 6.56 5.42 7.03 18.92
AIQUY
Air Liquide SA ADR		 0.17 0.45% 37.98 30.69 24.81 4.70 4.10 4.36 15.61
AIQUF
L'Air Liquide S.A		 0.02 0.01% 189.41 30.66 24.51 4.69 4.05 4.36 15.61
SHW
Sherwin-Williams Co		 6.00 1.89% 322.90 33.33 27.40 3.38 20.60 3.88 21.36

Reports Covered

Stock Research & News

View All

Profile

BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It also develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.

BioNexus Gene Lab Corp Common stock

Menara UOA Bangsar, Kuala Lumpur, Malaysia, 59000

Key Executives

Name Title Year Born
Ms. Wei Li Leong CFO & Principal Accounting Officer 1989
Mr. Liong Tai Tan COO & Exec. Director 1959
Mr. Sook Keng Yeoh CEO & Director 1958
Ms. Yee Meng Wong Pres & Director 1985
Dr. Choong-Chin Liew Co-Founder, Chief Scientist & Scientific Adviser 1938
Mr. Kwan Wah Chan Marketing Mang. NA
Mr. Too Kam Tham Managing Director NA
Mr. Su-Leng Tan CEO & Director 1984
Mr. Kwan Wah Chan Marketing Manager NA
Mr. Su-Leng Tan CEO, Acting CFO, Secretary & Director 1983

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.